Annals of vascular surgery · 2026
Thromboelastography with Platelet Mapping-Guided Thromboprophylaxis in Patients with Diabetes Undergoing Infrainguinal Endovascular Revascularization.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patel Shiv S, Fouzdar Shezan, Bansal Radha, Bhatt Swechha, Lokhande Prajakta, Hollnagel Fauzia, Dua Anahita
Аннотация
BACKGROUND: Patients with diabetes represent one of the largest subgroups undergoing endovascular revascularization for peripheral artery disease (PAD) and remain at high risk for thrombosis and restenosis. Postprocedural antithrombotic management varies in practice and does not routinely measure platelet response. We evaluated whether thromboelastography with platelet mapping (TEG-PM)-guided thromboprophylaxis was associated with reduced target vessel thrombosis or clinically significant stenosis.
METHODS: We performed a prospective, single-center, sequential cohort study of patients (≥60 years) with diabetes undergoing infrainguinal endovascular revascularization for PAD. In the standard of care (SOC) cohort, postoperative thromboprophylaxis was determined by the treating surgeon. In the TEG-PM-guided cohort, serial postoperative TEG-PM measurements informed antiplatelet adjustment to meet prespecified platelet inhibition thresholds (30-86%). The primary outcome was target vessel thrombosis or clinically significant stenosis at 12 months.
RESULTS: Of 164 patients with diabetes, 62 received TEG-PM-guided thromboprophylaxis and 102 received SOC. At 12 months, target vessel thrombosis or clinically significant stenosis was lower with TEG-PM-guided therapy than SOC (9.7% vs. 25.5%; P = 0.013). TEG-PM-guided therapy was associated with lower unadjusted hazard of this outcome (hazard ratio [HR] 0.34; 95% confidence interval [CI] 0.14-0.84; P = 0.019), although this was not significant after adjustment (HR 0.48; 95% CI 0.19-1.24; P = 0.131). Major amputation, all-cause mortality, amputation-free survival, and clinically relevant nonmajor bleeding did not differ significantly at 12 months. No major bleeding occurred.
CONCLUSION: TEG-PM-guided thromboprophylaxis was associated with a lower 12-month rate of target vessel thrombosis or clinically significant stenosis without major bleeding, although this association was attenuated after multivariable adjustment. Future studies should determine whether TEG-PM-guided antiplatelet therapy adjustment improves target vessel outcomes in patients with diabetes.
METHODS: We performed a prospective, single-center, sequential cohort study of patients (≥60 years) with diabetes undergoing infrainguinal endovascular revascularization for PAD. In the standard of care (SOC) cohort, postoperative thromboprophylaxis was determined by the treating surgeon. In the TEG-PM-guided cohort, serial postoperative TEG-PM measurements informed antiplatelet adjustment to meet prespecified platelet inhibition thresholds (30-86%). The primary outcome was target vessel thrombosis or clinically significant stenosis at 12 months.
RESULTS: Of 164 patients with diabetes, 62 received TEG-PM-guided thromboprophylaxis and 102 received SOC. At 12 months, target vessel thrombosis or clinically significant stenosis was lower with TEG-PM-guided therapy than SOC (9.7% vs. 25.5%; P = 0.013). TEG-PM-guided therapy was associated with lower unadjusted hazard of this outcome (hazard ratio [HR] 0.34; 95% confidence interval [CI] 0.14-0.84; P = 0.019), although this was not significant after adjustment (HR 0.48; 95% CI 0.19-1.24; P = 0.131). Major amputation, all-cause mortality, amputation-free survival, and clinically relevant nonmajor bleeding did not differ significantly at 12 months. No major bleeding occurred.
CONCLUSION: TEG-PM-guided thromboprophylaxis was associated with a lower 12-month rate of target vessel thrombosis or clinically significant stenosis without major bleeding, although this association was attenuated after multivariable adjustment. Future studies should determine whether TEG-PM-guided antiplatelet therapy adjustment improves target vessel outcomes in patients with diabetes.